A detailed history of Ransom Advisory, LTD transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Ransom Advisory, LTD holds 10,626 shares of BMY stock, worth $497,403. This represents 0.2% of its overall portfolio holdings.

Number of Shares
10,626
Previous 12,026 11.64%
Holding current value
$497,403
Previous $542 Million 99.91%
% of portfolio
0.2%
Previous 0.24%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2025

Jan 06, 2026

SELL
$42.6 - $49.08 $59,640 - $68,712
-1,400 Reduced 11.64%
10,626 $497,000
Q3 2025

Oct 07, 2025

BUY
$43.31 - $48.98 $520,846 - $589,033
12,026 New
12,026 $542 Million
Q3 2025

Oct 03, 2025

SELL
$43.31 - $48.98 $577,149 - $652,707
-13,326 Closed
0 $542 Million
Q2 2025

Jul 08, 2025

SELL
$44.12 - $59.6 $22,060 - $29,800
-500 Reduced 3.62%
13,326 $617 Million
Q1 2025

May 20, 2025

BUY
$53.9 - $63.11 $745,221 - $872,558
13,826 New
13,826 $843 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $99.5B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Ransom Advisory, LTD Portfolio

Follow Ransom Advisory, LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ransom Advisory, LTD, based on Form 13F filings with the SEC.

News

Stay updated on Ransom Advisory, LTD with notifications on news.